Dr. Amar Surdhar, M.D., a psychiatrist and founder of Clarion Psychiatry, has announced his support for the HAS Foundation, a organization dedicated to advancing neurological health through science, innovation, compassionate care, and interdisciplinary collaboration. The announcement, made in New York, highlights the growing role of physicians in supporting efforts to address complex neurological and neurodegenerative conditions.
The HAS Foundation works to improve the lives of individuals and families affected by neurological conditions and brain trauma. Its mission includes bridging the gap between scientific discovery and meaningful patient impact. The Foundation addresses conditions such as ALS, Alzheimer’s disease, dementia, and Parkinson’s disease, while fostering collaboration among scientists, physicians, researchers, engineers, innovators, and healthcare professionals.
Beyond symptom management, the Foundation’s approach emphasizes research, rehabilitation, cognition, therapeutic innovation, and whole-person care. It seeks to connect emerging scientific discoveries with clinical applications and innovative solutions that can improve neurological health and quality of life. This focus on translating research into tangible patient benefits is central to its work.
For Dr. Surdhar, supporting the HAS Foundation reflects a shared belief that medicine must address not only illness but also the dignity, humanity, and overall well-being of every patient. “As a psychiatrist, I have seen how profoundly conditions affecting the brain can impact not only an individual, but an entire family,” said Dr. Amar Surdhar. “I chose to support the HAS Foundation because its mission recognizes that meaningful progress requires science, innovation and compassion working together. Our work in psychiatry is deeply connected to understanding the brain, human behavior and quality of life. Supporting an organization committed to advancing neurological health, recovery and innovative solutions is a natural extension of that commitment. Every breakthrough brings us closer to giving patients and families greater hope, dignity and possibility.”
The significance of the HAS Foundation’s mission is underscored by the ongoing challenges posed by neurological and neurodegenerative diseases. These conditions present complex hurdles for patients, caregivers, and the medical community. By creating opportunities for interdisciplinary collaboration and connecting research, technology, and clinical practice, the Foundation aims to accelerate the translation of scientific discoveries into solutions that make a tangible difference in patients’ lives.
Dr. Surdhar’s contribution also highlights the important role that physicians, researchers, philanthropists, and community leaders can play in supporting organizations working at the intersection of brain health, innovation, healing, and human-centered care. Through his support, Dr. Surdhar joins the HAS Foundation in championing a future in which individuals confronting neurological disease and brain trauma are met not only with better science and treatment possibilities but also with compassion, resources, and hope.
Dr. Surdhar is the founder of Clarion Psychiatry, a New York-based psychiatric practice focused on thoughtful, individualized mental health care. His approach emphasizes understanding the whole patient while combining clinical expertise with compassionate, personalized care. Clarion Psychiatry PLLC is dedicated to providing discreet, high-quality psychiatric care for executives and high-net-worth individuals, offering personalized evaluations, medication management, and telepsychiatry in Midtown Manhattan.
The HAS Foundation supports efforts focused on neurological health, scientific research, innovation, rehabilitation, and collaboration across disciplines. Its mission centers on improving outcomes and quality of life for individuals and families affected by neurological disease and brain trauma. Dr. Surdhar’s support brings additional attention to the Foundation’s work and the critical need for continued investment in brain health research and care.
